文献速递新发突发、热带与寄生虫病

体外评估加纳普拉西/苯芴醇组合在青蒿素耐药背景下的抗恶性疟原虫活性

In vitro evaluation of ganaplacide/lumefantrine combination against Plasmodium falciparum in a context of artemisinin resistance.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

加纳普拉西(KAF156)是进入III期临床试验的新型抗疟候选药,拟与苯芴醇联用。本研究用携带不同pfk13突变及其他抗疟药耐药标志的青蒿素耐药虫株进行体外评估,发现KAF156活性不受pfk13、pfcrt、pfmdr1、pfmdr2、pfdhps、pfdhfr基因突变或pfmdr1扩增影响,单用及与苯芴醇联用对青蒿素耐药虫株(包括静息状态)均有活性。

要点

  • KAF156活性不受pfk13、pfcrt、pfmdr1、pfmdr2、pfdhps、pfdhfr突变或pfmdr1扩增影响。
  • KAF156单用及与苯芴醇联用对青蒿素耐药虫株有活性,包括静息状态虫株。
  • 体外结果提示多重耐药虫株可能不影响KAF156疗效,为三联ACT提供依据。

核心结论

  • 体外结果表明,当前现场流行的多重耐药虫株可能不影响KAF156疗效,为KAF156用于三联ACT以尽可能长期保留青蒿素的使用提供了鼓励性信号。

研究设计与样本

  • 体外研究,使用一组携带不同pfk13突变及其他抗疟药耐药标志的青蒿素耐药虫株进行评估。

主要发现

  • KAF156活性不受pfk13、pfcrt、pfmdr1、pfmdr2、pfdhps和pfdhfr基因突变或pfmdr1扩增影响。
  • KAF156单用及与苯芴醇联用对青蒿素耐药虫株有活性,包括虫株处于静息状态时。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ganaplacide, also known as KAF156, is among the new antimalarial drug candidates that have successfully reached Phase III clinical trials, and is proposed in combination with lumefantrine. This combination could replace the current front-line artemisinin-based combination therapies (ACTs) in case of Plasmodium falciparum resistance to both artemisinins and partner drugs. Indeed, the African continent, where the malaria burden is the highest, is currently experiencing worrying multiple emergences and spread of artemisinin resistance, which urges for the exploration of the antiparasitic properties of KAF156 in this context. OBJECTIVES AND METHODS: The objectives of this work were firstly to evaluate the risk of cross-resistance between artemisinins and KAF156 alone, and in combination with lumefantrine, using a panel of artemisinin-resistant strains carrying different pfk13 mutations and markers of other antiplasmodial drug resistances; secondly to explore in vitro the relevance of combining KAF156 and lumefantrine with artemisinins, based on the model of triple ACTs. RESULTS: Our results highlighted that KAF156 activity was not impaired by mutations in pfk13, pfcrt, pfmdr1, pfmdr2, pfdhps and pfdhfr genes or by pfmdr1 amplification. Moreover, we demonstrated that KAF156 alone and in combination with lumefantrine was active against artemisinin-resistant parasites, including when they are quiescent. CONCLUSIONS: All these in vitro results evidence that multi-drug resistant parasites currently in circulation in the field might not affect KAF156 efficacy, and are encouraging signs for KAF156 use in a triple ACT to preserve the use of artemisinins for as long as possible.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Manaranche J, Laurent M, Tressieres R, et al. In vitro evaluation of ganaplacide/lumefantrine combination against Plasmodium falciparum in a context of artemisinin resistance. J Antimicrob Chemother. 2024. PMID: 39206510. doi:10.1093/jac/dkae300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。